Interview with Wu Xiaobing, General Manager, Pfizer China
It seems like there’s a lot to be happy about here: Pfizer is ranked number 1 multinational R&D-based biopharmaceutical company in China, where you also have two world-class R&D centers…
Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That’s why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them.
To ensure we can continue to deliver on our commitments to the patients, customers and shareholders who rely on us, we are focused on improving the way we do business; on operating with transparency in everything we do; and on listening to the views of all of the people involved in health care decisions. Through working in partnership with everyone from patients to health care providers and managed care organizations to world governments and non-governmental organizations, our goal is to ensure that people everywhere have access to innovative treatments and quality health care.
Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That’s why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them.
To ensure we can continue to deliver on our commitments to the patients, customers and shareholders who rely on us, we are focused on improving the way we do business; on operating with transparency in everything we do; and on listening to the views of all of the people involved in health care decisions. Through working in partnership with everyone from patients to health care providers and managed care organizations to world governments and non-governmental organizations, our goal is to ensure that people everywhere have access to innovative treatments and quality health care.
Contact:
Address: German Center, Tower 1, 5F, 88 Keyuan Rd, Pudong Zhangjiang Hi-Tech Park, Shanghai, P.R.China 201203
Tel: (021) 28935888
It seems like there’s a lot to be happy about here: Pfizer is ranked number 1 multinational R&D-based biopharmaceutical company in China, where you also have two world-class R&D centers…
Rogier Janssens, GM of the Biopharma business of Merck KGaA, Darmstadt, Germany in China, shares the highlights of his first 16 months at the affiliate; the impact of the regulatory…
Kang Wei, managing director for the R&D-based Pharmaceutical Association Committee (RDPAC) under the China Association of Enterprises with Foreign Investment, shares her priorities for RDPAC in the next few years,…
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis and Kevin Allison is the director of geo-technology. Together they look at last week’s shock revelation of two CRISPR* babies who were born in China and…
Steven Lynch, managing director of the British Chamber of Commerce in China, introduces the Chamber’s activities in support of their members, the research they are undertaking to produce a position…
Song Ruilin, executive president of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), discusses his association’s mandate, key achievements and the future of innovative Chinese pharmaceuticals and biotech. …
Following China’s vaccine scandal earlier this year, the country’s drug administration has considerably tightened up inspection processes of vaccine manufacturers which is causing shortages and raising the risk of widespread…
China’s stupendous economic resurgence over the past four decades never ceases to awe, but what has captured attention in recent years has been the country’s international awakening. Against a nasty…
Cash has always ruled the start-up world and when it comes to the healthcare and life sciences sphere, the heavy investment required for R&D and the long timelines make it even…
The Greater Bay Area’s – and in particular, Shenzhen’s – prowess in life sciences manufacturing and development must also be attributed to the decades of experience and expertise gained from…
The Honorable William Zarit, Chairman of the American Chamber of Commerce in Beijing (AmCham Beijing), shares the insights gained over his 25 years in China, the key priorities of AmCham…
Eric Bouteiller, formerly with Ipsen (most recently as SVP Asia PC Operations based in Beijing) and chairman of the R&D-based Pharmaceutical Association Committee (RDPAC) till December 2017, speaks in his…
In 2013, Chinese President Xi Jinping launched the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) initiative, corralling the two Special Administrative Regions (SARs) of Hong Kong and Macao with Guangdong, one…
See our Cookie Privacy Policy Here
